Short-term effects of the smoke-free legislation on haemostasis and systemic inflammation due to second hand smoke exposure

Summary

It was the objective of this study to assess the effect of the implementation of the smoke-free legislation on haemostasis and systemic inflammation in second-hand smoking (SHS)-exposed healthy volunteers. Fibrin-rich clot properties, platelet reactivity and inflammatory biomarkers were measured before and four months following the implementation of the smoke-free legislation in gender and age-matched healthy volunteers exposed (n=23, exposed) and unexposed (n=23, controls) to occupational SHS. The primary objective was to compare fibrin-rich clot stiffness before and after implementation of the smoke-free legislation. There was 40% reduction in fibrin-rich clot stiffness following the implementation of the smoke-free legislation in SHS-exposed volunteers (17 ± 7 vs. 10.6 ± 7 dynes/cm², before and after, respectively, p=0.001). These dramatic changes were associated with a 20% reduction in fibrin fiber density (p<0.01) and a 20% reduction inclot lysis time (p=0.05). No change in fibrin properties was observed in the control group of SHS-unexposed volunteers related to the implementation of the smoke-free legislation. Of interest, neither platelet reactivity nor systemic inflammatory biomarkers were changed in either group. The smoke-free legislation is associated with significant changes in fibrin-rich clot properties toward a less thrombogenic conformation with a better fibrinolysis response while neither platelet reactivity nor systemic inflammatory biomarkers are modified. These improvements may explain the observed reduction in acute coronary syndrome following the implementation of the smoke-free legislation.

Keywords

Second hand smoke - smoke-free legislation - fibrin-clot - platelet reactivity - inflammatory biomarkers

^* AERER: impact de l’Arrêt de l’Exposition au tabagisme passif sur les paramètres Rhéologiques, inflammatoires, Endothéliaux et de Réactivité plaquettaire

• References

• 1 Jonas MA. et al. Statement on smoking and cardiovascular disease for health care professionals. American Heart Association. Circulation 1992; 86: 1664-1669.
• 2 Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 2004; 43: 1731-1737.
• 3 Barua RS. et al. Reactive oxygen species are involved in smoking-induced dysfunction of nitric oxide biosynthesis and upregulation of endothelial nitric oxide synthase: an in vitro demonstration in human coronary artery endothelial cells. Circulation 2003; 107: 2342-2347.
• 4 Barnoya J, Glantz SA. Cardiovascular effects of secondhand smoke: nearly as large as smoking. Circulation 2005; 111: 2684-2698.
• 5 Teo KK. et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet 2006; 368: 647-658.
• 6 Oberg M. et al. Worldwide burden of disease from exposure to second-hand smoke: a retrospective analysis of data from 192 countries. Lancet 2011; 377: 139-146.
• 7 Lightwood JM, Glantz SA. Declines in acute myocardial infarction after smoke-free laws and individual risk attributable to secondhand smoke. Circulation 2009; 120: 1373-1379.
• 8 Mackay DF. et al. Meta-analysis of the effect of comprehensive smoke-free legislation on acute coronary events. Heart 2010; 96: 1525-1530.
• 9 Collet JP. et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 2006; 26: 2567-2573.
• 10 Barua RS. et al. Effects of cigarette smoke exposure on clot dynamics and fibrin structure: an ex vivo investigation. Arterioscler Thromb Vasc Biol 2010; 30: 75-79.
• 11 Rop PP. et al. Determination of nicotine and its main metabolites in urine by high-performance liquid chromatography. J Chromatogr 1993; 612: 302-309.
• 12 Verbeke M. Linear Mixed Models for Longitudinal Data. 2nd ed New York: Springer-Verlag; 2001
• 13 Sims M. et al. Short term impact of smoke-free legislation in England: retrospective analysis of hospital admissions for myocardial infarction. Br Med J 2010; 340: c2161.
• 14 Scott EM. et al. Genetic and Environmental Determinants of Fibrin Structure and Function Relevance to Clinical Disease. Atheroscler Thromb Vasc Biol 2004; 24: 1558-1566.
• 15 Collet JP. et al. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol 2000; 20: 1354-1361.
• 16 Undas A. et al. Fibrin clot properties are altered in patients with chronic obstructive pulmonary disease. Beneficial effects of simvastatin treatment. Thromb Haemost 2009; 102: 1176-1182.
• 17 Mills JD. et al. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation 2002; 106: 1938-1942.
• 18 Morita H. et al. Only two-week smoking cessation improves platelet aggregability and intraplatelet redox imbalance of long-term smokers. J Am Coll Cardiol 2005; 45: 589-594.
• 19 Takajo Y. et al. Augmented oxidative stress of platelets in chronic smokers. Mechanisms of impaired platelet-derived nitric oxide bioactivity and augmented platelet aggregability. J Am Coll Cardiol 2001; 38: 1320-1327.
• 20 Fusegawa Y, Handa S. Platelet aggregation induced by ADP or epinephrine is enhanced in habitual smokers. Thromb Res 2000; 97: 287-295.
• 21 Rubenstein D. et al. Differences between mainstream and sidestream cigarette smoke extracts and nicotine in the activation of platelets under static and flow conditions. Circulation 2004; 109: 78-83.
• 22 Undas A. et al. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost 2006; 4: 1029-1036.
• 23 Blache D. Involvement of hydrogen and lipid peroxides in acute tobacco smoking-induced platelet hyperactivity. Am J Physiol 1995; 268: H679-685.
• 24 Fusegawa Y. et al. Platelet spontaneous aggregation in platelet-rich plasma is increased in habitual smokers. Thromb Res 1999; 93: 271-278.
• 25 Roitman EV. et al. Oxidatively modified fibrinogen modulates blood rheological parameters. Bull Exp Biol Med 2004; 138: 467-469.
• 26 Tetik S. et al. Oxidative modification of fibrinogen affects its binding activity to glycoprotein (GP) IIb/IIIa. Clin Appl Thromb Hemost 2010; 16: 51-59.
• 27 Venn A, Britton J. Exposure to secondhand smoke and biomarkers of cardiovascular disease risk in never-smoking adults. Circulation 2007; 115: 990-995.
• 28 Jefferis BJ. et al. Secondhand smoke (SHS) exposure is associated with circulating markers of inflammation and endothelial function in adult men and women. Atherosclerosis 2010; 208: 550-556.
• 29 Yanbaeva DG. et al. Systemic effects of smoking. Chest 2007; 131: 1557-1566.
• 30 Rudez G. et al. Biological variation in inflammatory and hemostatic markers. J Thromb Haemost 2009; 7: 1247-1255.
• 31 Bura A. et al. Impact of smoking prohibition in bars, restaurants and discotheques on employees endothelial function: the DILATER study. European Heart J. 2009 Suppl.: Abstract 584.